Compare Ishares Msci Brazil ETF (EWZ) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs GSK plc — how do they compare? Ishares Msci Brazil ETF trades at $43.48 (market cap $11.30B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 8.1× Ishares Msci Brazil ETF's market cap, and GSK plc pays a 3.9% dividend while Ishares Msci Brazil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and GSK plc for 93 Days on average.
| EWZ | GSK | |
|---|---|---|
Market Cap | $11.30B | $91.88B |
Volume | 44,036,597 | 7,730,529 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $61.18 |
52-Week Low | $28.79 | $43.24 |
Typical Hold Time | 50 Days | 93 Days |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, is trading at $43.465, up 2.58% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows strong institutional interest with unusual options activity and new positions from firms like Empowered Funds. Recent news highlights Brazil's upcoming election as a key market driver, with investors positioning for potential policy shifts under different candidates.
The outlook for EWZ hinges on Brazil's political landscape and commodity trends. Investment opportunities include geographic diversification and exposure to Brazilian stimulus policies, while risks involve election volatility and US-Brazil trade tensions. Wall Street shows cautious optimism with significant institutional accumulation despite competitive pressure from lower-fee alternatives like FLBR.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
